Thrombocytopenic purpura

Summary

Thrombocytopenic purpura (MONDO:0043768) is a disease and 8 clinical trials. Top therapeutic interventions include romiplostim and honey. A subtype of thrombocytopenia — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 8

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	thrombocytopenic purpura
Mondo ID	MONDO:0043768
MeSH	D011696
NCIT	C26870
SNOMED CT	302873008
UMLS	C0857305
MedGen	208992
GARD	0025866
Is cancer (heuristic)	no

Also known as: purpura, thrombopenic · purpuras, thrombocytopenic · purpuras, thrombopenic · thrombocytopenic purpura · thrombocytopenic purpuras · thrombopenic purpura · thrombopenic purpuras

Disease family

This is a subtype of thrombocytopenia. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › hematologic disorder › blood platelet disease › thrombocytopenia › thrombocytopenic purpura

Related subtypes (5): acquired thrombocytopenia, thrombocytopenia due to immune destruction, autoimmune thrombocytopenia, neonatal thrombocytopenia, inherited thrombocytopenia

Subtypes (2): autoimmune thrombocytopenic purpura, thrombotic thrombocytopenic purpura

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 8.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	4
PHASE3	3
PHASE1/PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00415532	PHASE3	COMPLETED	Romiplostim (AMG 531) Versus Medical Standard of Care for Immune (Idiopathic) Thrombocytopenic Purpura
NCT00508820	PHASE3	COMPLETED	An Open Label Study of Romiplostim in Adult Thrombocytopenic Subjects With ITP
NCT01444417	PHASE3	COMPLETED	Safety and Efficacy Study of Romiplostim to Treat Immune Thrombocytopenia (ITP) in Pediatric Patients
NCT00117143	PHASE1/PHASE2	COMPLETED	Amgen Megakaryopoiesis Protein 2 (AMG 531) in Thrombocytopenic Subjects With Immune Thrombocytopenic Purpura (ITP)
NCT00454857	Not specified	COMPLETED	Retrospective & Prospective Observational Study of Patients With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)
NCT01462916	Not specified	TERMINATED	Honey in Chronic Immune Thrombocytopenia
NCT01648556	Not specified	COMPLETED	Research of Predictive Factors to Immune Thrombopenic Purpura
NCT03244410	Not specified	UNKNOWN	Lymphocyte Counts in Immune Thrombocytopenic Purpura

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
ROMIPLOSTIM	4	4
HONEY	3	1